ORIC Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed this Current Report on April 28, 2020, in connection with the closing of its initial public offering (IPO). The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol ORIC.
Financial Metrics and Liquidity
This filing does not provide financial statements or clear values for revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity, or other operating metrics. The filing states that the IPO closed with the sale of 8,625,000 shares of common stock, including 1,125,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. IPO proceeds are not stated in the provided filing text.
Material Changes Versus the Prior Comparable Period
- The company completed its IPO on April 28, 2020.
- The company filed an amended and restated certificate of incorporation in connection with the IPO.
- The company adopted amended and restated bylaws effective April 28, 2020.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance or operating outlook is provided in this Form 8-K. The filing refers investors to the IPO prospectus for descriptions of the amended organizational documents, risk factors, and capital stock provisions.
The company stated that it may disclose material information through SEC filings, its website, press releases, public conference calls, and public webcasts. The Regulation FD disclosure and attached press release are furnished rather than filed for purposes of Exchange Act Section 18, except where expressly incorporated by reference.
Important Facts for Investors to Verify
- Review the IPO prospectus for the offering price, gross and net proceeds, underwriting discounts, use of proceeds, and dilution.
- Review Exhibits 3.1 and 3.2 for the precise terms of the amended certificate of incorporation and bylaws.
- Confirm the final IPO share count, including the 1,125,000 shares issued through the underwriters’ option.
- Review the company’s subsequent periodic filings for post-IPO cash, liquidity, operating expenses, clinical development spending, and funding requirements.
- Review the prospectus risk factors for clinical, regulatory, financing, and commercialization risks.